Abstract | Rapid-onset cardiovascular disease (CVD) is a major concern for many patients with systemic lupus erythematosus (SLE). Cardiovascular events occur more frequently and with earlier onset in patients with SLE compared with healthy individuals. Traditional risk factors, such as altered lipid levels, aging and smoking, do not fully explain this increased risk of CVD, strongly suggesting that autoimmunity contributes to accelerated atherosclerosis. Altered immune system function is recognized as the primary contributor to both the initiation and progression of atherosclerosis. Multiple manifestations of autoimmunity, including changes in cytokine levels and innate immune responses, autoantibodies, adipokines, dysfunctional lipids, and oxidative stress, could heighten atherosclerotic risk. In addition, multiple SLE therapeutics seem to affect the development and progression of atherosclerosis both positively and negatively. SLE-specific cardiovascular risk factors are beginning to be discovered by several groups, and development of a comprehensive, clinically feasible biomarker panel could be invaluable for identification and treatment of patients at risk of developing accelerated atherosclerosis. Here, we discuss the epidemiology of CVD in SLE and the implications of immune system dysfunction on the development and progression, monitoring and treatment of atherosclerosis in individuals with this disease.
Introduction
Atherosclerosis was once believed to be caused by passive deposition of lipids into arterial walls, with subsequent covering of the deposits by smooth muscle and endo thelial cells; however, we now know that this disease results from dynamic accumulation of oxidized chol esterol over time, primarily driven by activity of the immune system. 1 Not surprisingly, therefore, many dis eases characterized by autoimmunity and immune system dysfunction are associated with markedly increased morbidity and mortality due to cardiovascular disease (CVD). Moreover, CVD associated with auto immunity is often defined by accelerated athero sclerosis, with symp toms becoming apparent at an earlier age compared with healthy individuals.
Researchers and physicians studying accelerated athero sclerosis in systemic lupus erythematosus (SLE) have three main goals: to understand the biological differences in the pathogenesis of CVD between indivi duals with and without SLE; to identify atrisk patients before the onset of atherosclerosis; and to develop novel therapeutic options for prevention of athero sclerotic progression. In this Review, we will discuss the epi demiology and patho genesis of SLEdriven athero sclerosis, the essential role of a dysregulated immune system in the progression of CVD, and strategies for minimizing and treating athero sclerosis in patients with SLE.
Epidemiology of atherosclerosis in SLE
Increased risk of CVD in SLE Increased risk of CVD in patients with SLE was first described in 1976. 2 The authors of this study reported that deaths that occurred <1 year after onset of SLE were directly related to SLE disease activity, whereas mortal ity in patients with longer disease duration was pri marily attributable to CVD. 2 Subsequent analysis confirmed this bimodal pattern of SLEassociated death, although more recent data suggest that, owing to improvements in SLE diagnosis and treatment, CVD and infection are the leading causes of SLE mortality-regardless of time after diagnosis. 3 The overall risk of myocardial infarction (MI) in patients with SLE is 10fold higher than in the general population, even after accounting for traditional Framingham risk factors. 4 This risk was found to be even more pronounced in women with SLE aged 35-44 years, who were over 50 times more likely to have a MI than controls matched for age and gender in the Framingham Offspring Study. 5 Evidence from subclinical measures of CVD Despite the increased risk of cardiovascular events in patients with SLE, the absolute number of events per year in any given cohort is small; thus, research into bio markers and treatment strategies for CVD in patients with SLE has focused on measurement of multiple s urrogate, subclinical measures of atherosclerosis.
Several groups have performed crosssectional or lon gitudinal studies in which ultrasonography was used to measured carotid plaque burden as a surrogate marker of subclinical atherosclerosis. [6] [7] [8] These studies revealed that carotid plaques were increased more than twofold in patients with SLE compared with indivi duals without SLE, independent of known risk factors for CVD, 6 and progressed rapidly. 7, 8 Furthermore, more than three times as many patients with SLE than healthy controls had coro nary artery calcification, measured using electronbeam CT. 9 Moreover, using dualisotope single photon emis sion CT (SPECT) myocardial perfusion imaging, 40% of patients with SLE were found to have perfusion defects indicative of subclinical athero sclerosis. 10 In a separate study, flowmediated dilation measurements revealed that >50% of patients with SLE examined had endothelial dysfunction versus 26% of controls.
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In addition to abnormalities of the macrovasculature in patients with SLE, evidence suggests that coronary microvascular dysfunction can also occur in these indivi duals; reduced coronary flow reserve-measured using PET-was reported in patients with SLE, despite normal coronary artery function. 12 Although the measures of subclinical atherosclerosis described above are closely linked to coronary events in the general population, 13 only abnormal myocardial perfusion has thus far been associ ated with cardiovascular events in individuals with SLE, which is important to note. 10 
Pathogenesis of atherosclerosis in SLE
Why patients with SLE or other autoimmune diseases are at increased risk of atherosclerosis remains unclear. The traditional Framingham cardiac risk factors 14 con tribute to atherosclerotic risk but do not fully explain the increased risk of CVD associated with SLE. 4 As athero sclerosis is currently appreciated to be a process intimately intertwined with the immune system, multiple aspects of autoimmunity probably contribute to accelerated CVD in concert with traditional cardiovascular risk factors. In the following sections we will discuss our current understand ing of the mechanisms that drive athero sclerosis, and how these processes might be affected by dysregulation of the immune system in SLE.
Atherosclerosis initiation and progression

Monocyte and T-cell recruitment
Lowdensity lipoproteins (LDL) are complex particles that carry apolipoprotein B100, cholesterol and other lipids, and various antioxidant molecules. When trapped in the subendothelial space, LDL can be modified by reac tive oxygen species (ROS), resulting in production of oxi dized LDL (oxLDL) and subsequent activation of ar terial endothelial cells (ECs). These events are commonly regarded as initiating events in atherogenesis (Figure 1 ). Monocytes are able to interact with and adhere to acti vated ECs via adhesion molecules that are upregulated on both cell types and increased cytokine release (CCmotif chemokine ligand 2 [also known as monocyte chemo attractant protein 1], IL6 and TNF). 15 Monocytes adhere to ECs, then migrate to the intima and differentiate into macro phages. Monocyte activation is generally increased in SLE compared with controls, but monocyte activation (as determined by measurement of serum neopterin) Key points ■ Cardiovascular disease (CVD) is a substantial contributor to morbidity and mortality in patients with systemic lupus erythematosus (SLE) ■ SLE-specific risk factors for accelerated atherosclerosis exist, but are poorly understood ■ Endothelial cell dysfunction plays a major part in accelerated atherosclerosis in patients with SLE ■ Identification of SLE-specific mechanisms of, and biomarkers, for accelerated atherosclerosis should lead to the development of novel screening protocols for early detection of CVD and discovery of new therapeutic targets
was not found to correlate with increased coronary at herosclerosis (Figure 1 ). 16 T cells are also recruited to nascent atherosclerotic plaques through similar mechanisms, although in lower numbers. The T cells involved are predominantly CD4 + Thelper1 (T H 1) cells, which secrete proinflam matory and proatherogenic IFNγ.
Progression of atherosclerotic plaques
Macrophages within the intima of the artery phago cytose abundant oxLDL and become foam cells, which form the basis of the plaque lesion ( Figure 1) . Smooth muscle cells then migrate and proliferate in response to cytokines, growing around the expanding lesion and encroaching on the vessel lumen, leading to plaque fibrosis. MI can occur when the fibrous cap that is formed over the plaque rup tures or after platelet aggregation in an occluded artery. 15 Protective role of high-density lipoprotein Highdensity lipoproteins (HDL) protect against athero sclerosis in two main ways (Figure 1 ). First, reverse cho lesterol transport, where cholesterol and phospholipids are shuttled out of foam cells, is mediated by the inter actions of lipoproteins that constitute HDL with lipid trans porters on foam cells. Apolipoprotein AI (apoAI), the most abundant protein component in HDL, is necessary in pro moting reverse cholesterol transport. 17 Second, normal HDL functions as an antioxidant, and both proteins and lipids in LDL are protected from accumulation of oxidative modifications by the presence of normal HDL.
Vascular damage and EC dysfunction in SLE
In addition to earlyonset atherosclerosis in compari son with healthy controls, patients with SLE are at risk of accelerated vascular damage. Studies have shown that blood flow at the forearm, brachial artery and heart is markedly impaired in individuals with SLE. 18, 19 Evi dence suggests that SLE accelerates vascular damage, and that vascular repair mechanisms are ineffective in this dis ease. Patients with SLE have high levels of circulating apop totic ECs-indicative of increased vascular damage-and lower levels of circulating endothelial progenitor cells (EPCs) that are involved in the repair of damaged ar terial tissues. 20, 21 Generation of reparative myelomono cytic circulating angiogenic cells (CACs) is also impaired in these individuals. 21 Secretion of IFNα, mainly by plasmacytoid den dritic cells (pDCs), can induce EC and EPC apoptosis 22 
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and prevent the differentiation of EPCs 21, 22 and CACs 21 to mature ECs ( Figure 1 ). In addition, IFNα promotes conversion of CACs to dendritic cells, 21 and thus might impede the repair of vascular damage. pDC secretion of IFNα could be stimulated, in part, by lowdensity granulo cytes (LDG) undergoing NETosis-a form of cell death characterized by expulsion of 'neutrophil extra cellular traps' (NETs), meshlike strands of chromatin fibers. 23 Interestingly, LDG are substantially more abun dant in patients with SLE than in controls 22 and, in addi tion to driving expression of high levels of IFNα by pDCs, demonstrate increased NETdependent EC cytotoxicity. 23 Together, these findings suggest that immune system dys function in SLE-including increased IFNα production and NETosis-could potentiate vascular damage and prevent repair processes (Figure 2 ).
Autoantibodies, cytokines and atherosclerosis
Antiphospholipid antibodies
The association of autoantibodies with increased CVD in patients with SLE has been studied by multiple groups. Mixed results have been obtained regarding the role of antiphospholipid antibodies (aPL) in the develop ment of atherosclerosis in humans. 24 Patients with pri mary antiphospholipid syndrome (APS), especially those >40 years old, have greater carotid intima-media thicken ing (CIMT) at multiple artery sites than con trols. 25 Furthermore, high aPL antibody levels correlated with increased MI risk in otherwise healthy men. 26, 27 Although estimates of aPL positivity in SLE range from 20-80%, 28 little agreement has been reached on whether the presence of aPL correlates with accelerated athero sclerosis. 6, 8, 9, [29] [30] [31] Evidence suggests that patients with APS do not have substantially greater EC dysfunction than controls. 32 Nevertheless, aPL might contribute to a 'two hit hypo thesis' , in which the circulating autoanti bodies con tribute to early EC dysfunction in SLE via interac tion with β 2 glycoprotein 1 on vascular walls but other thrombo tic events are necessary to trigger plaque and clot formation ( Figure 2 ).
Anti-oxLDL antibodies
IgM antibodies that recognize oxLDL are generally consid ered to be protective against atherosclerosis, whereas IgG antioxLDL autoantibodies seem to accelerate disease. 33 The presence of antioxLDL antibodies increases the risk of atherosclerosis in humans with SLE ( Figure 2 ). AntioxLDL antibodies developed after antilipoprotein lipase autoanti bodies were detected, and were associated with increased atherosclerotic risk, in a cohort of patients with high SLE disease activity. 34 The mechanism underlying the pro atherogenic effect of IgG antioxLDL antibodies remains unknown, but defective clearance of immune complexes (as evident in lupus nephritis) or the presence of aggre gated oxLDL in the subendothelial space could explain the increased atherosclerotic risk in patients with SLE.
Anti-apolipoprotein A-I antibodies
Approximately 20% of nonautoimmune patients with acute coronary syndromes were found to have circulating antiapoAI antibodies, compared with only 1% of healthy individuals, 35 suggesting that these auto antibodies have a role in atherosclerosis development ( Figure 2 ). In the same study, 13% of patients with SLE and/or APS had circulat ing antiapoAI antibodies, 35 whereas the prevalence noted in another investigation was 32.5% in patients with SLE and 22.9% in patients with primary APS. 36 Furthermore, the presence of autoantibodies targeting apoAI and HDL corre lated with increased SLE disease activity. 37 As apoAI is a major anti inflammatory component of HDL, antiapoAI autoantibodies are presumed to render the atheroprotective capabilities of apoAI and HDL Dashed arrows indicate processes that are minimized by these protective mechanisms. b | During initiation and progression of atherosclerosis in SLE, protective mechanisms are overcome. HDL becomes piHDL, which is present in almost half of patients with SLE, and augments oxLDL production. oxLDL activates ECs to release proinflammatory cytokines, stimulating monocytes to bind the EC layer and transmigrate into the intima. The monocytes differentiate into foam cells, assisted by increased piHDL, oxLDL, TNF and homocysteine levels, all of which can be elevated in patients with SLE. High homocysteine levels also increase ROS and EC damage. Defective, apoptotic and reduced numbers of EPCs and CACs diminishes the EC repair system. Together, all of these processes increase arterial plaque burden. Abbreviations: CAC, circulating angiogenic cell; EC, endothelial cell; EPC, endothelial progenitor cell; HDL, high-density lipoprotein; LDL, low-density lipoprotein; oxLDL, oxidized LDL; piHDL, proinflammatory HDL; ROS, reactive oxygen species; SLE, systemic lupus erythematosus; TNFR, TNF receptor. ineffective, but this theory needs to be proven. Additional studies are required to confirm whether the presence of antiapoAI anti bodies correlates with atherosclerosis ini tiation and progression in the general population and in patients with SLE.
Cytokines
Many cytokines are found in atherosclerotic plaques and are known to contribute-both positively and ne gatively -to plaque development and progression in patients without autoimmune disease. 38 Less is currently known about the part many of these cytokines play in acceler ated atherosclerosis in patients with SLE. This gap in our knowledge is somewhat surprising, given that dysregu lated immunity defines SLE, although this area of research is the focus of a number of groups and will certainly be better understood in the future.
T H 1 cells are abundant in atherosclerotic lesions, and IFNγ-the prototypical T H 1 cytokine-promotes plaque instability by reducing collagen production and inhibiting growth of SMCs and ECs. 39 IFNγ also promotes foam cell formation as well as plaque rupture, 40 although no studies have directly examined the role of IFNγ in SLEdriven accelerated atherosclerosis.
IL12 is expressed by macrophages, SMCs, and ECs, and is a major cytokine involved in T H 1 differentiation. High levels of IL12 have been found in atherosclerotic plaques in patients without autoimmune disease, and IL12 was expressed by monocytes treated with oxLDL in vitro. 41 TNF and IL1 are potent macrophage activators that can promote arterial inflammation and EC dysfunction. 42 In addition, TNF and IL1 stimulate monocyte differenti ation into macrophages and foam cells. High plasma TNF levels, 43, 44 together with high TNF receptor levels, 43 have been observed in patients with SLE and CVD, compared with either patients with SLE but no detectable CVD or individuals without SLE. Conversely, low IL1 levels seem to promote IFNαdriven vascular damage in SLE, 45 suggesting that the proangiogenic effects of high levels of IL1 are both beneficial (in promoting vascular repair) and deleterious (stimulating foam cell formation).
High serum IL6 levels caused by acute inflammation lead to the production of Creactive protein, and both of these proteins are independent markers of increased mor tality in CVD. However, the role of IL6 in atherosclerotic progression in SLE is unclear; high levels of IL6 have been linked to atherosclerotic risk in some SLE cohorts, 46, 47 but not in other crosssectional 6 and longitudinal 48 studies. IL17 is secreted by Thelper17 (T H 17) cells and is thought to promote SLE disease activity. 49 Contradic tory data exist with regard to the role of IL17 in non autoimmune CVD, 38 although results presented in two papers, published in 2011, suggest that IL17 pro motes athero sclerosis in autoimmune diseases. 50, 51 In atherosclerosis prone mice, treatment with mycopheno late mofetil (MMF) decreased serum IL17 levels, Tcell infiltrates in the plaques and total plaque size compared with untreated animals. 50 In addition, impaired endo thelial func tion corre lated with high IL17 levels in patients with rheumatoid arthritis (RA), suggesting a role for this cytokine in atherogenesis. 51 The role of IL17 in human SLE remains unknown.
Regulatory T (T REG ) cells are believed to have a protec tive role in atherosclerosis initiation, and might improve the stability of any plaques formed, 52 although data that support this theory are limited at present. The T REG cell cytokine TGFβ, in contrast to the cytokines discussed above, is probably protective against plaque formation in the general population. 53 Low serum TGFβ levels have also been found to correlate with increased CIMT and LDL levels in patients with SLE, but not control individuals. 54 Another cytokine produced by T REG cells, IL10, also seems to prevent atherogenesis in a mouse model of atherosclerosis (Ldlr -/-). 38 However, in a study in which Ldlr -/-mice were lethally irradiated then reconstituted with bone marrow from an SLEprone strain (to make Figure 2 | Continuum of SLE-specific and traditional risk factors for CVD. SLE-specific (left; red), shared (middle), and traditional (right; blue) risk factors for atherosclerosis are shown as a continuum, whereby risk factors on the left-hand side of each group might be more crucial in SLE-mediated accelerated atherosclerosis. Immune system dysfunction and subsequent vascular and renal damage in SLE, together with the influence of traditional cardiovascular risk factors, probably contribute to accelerated atherosclerosis and the increased risk of CVD in patients with SLE compared with the general population. In addition, SLE therapeutics could affect CVD risk, either positively or negatively. Owing to the range of factors that might have a role in accelerated atherosclerosis in SLE, identification and treatment of at-risk patients will probably require an integrated approach. Abbreviations: aPL, anti-phospholipid antibodies; ApoA-I, apolipoprotein A-I; CVD, cardiovascular disease; LDG, low-density granulocytes; oxLDL, oxidized low-density lipoprotein; piHDL, proinflammatory high-density lipoprotein; SLE, systemic lupus erythematosus; TLR, Toll-like receptor. 56 In addition, endogenous molecules, such as certain lipids and nucleic acids, can also act as ligands for TLRs and trigger TLR signaling. In vitro studies suggest that when oxLDL binds TLR4 and CD14 on macrophages, phagocytosis of apop totic cells is inhibited, expression of the scavenger receptor CD36 is upregulated, and uptake of oxLDL is increased, which might lead to initiation of atherosclerosis. 57 The roles of TLRs and innate immunity in athero sclero sis associated with rheumatic diseases are poorly under stood. IFNα upregulation-resulting from increased TLR7 and TLR9 signaling after exposure to increased levels of endogenous nucleic acids-has been postulated to promote atherosclerosis in patients with SLE by promot ing macrophage expression of TLR2 and TLR4. 58 Thus, TLR7-TLR9 signaling could influence athero genesis through production of IFNα, which has been implicated in endothelial damage and inhibition of vascular repair mechanisms, as described above.
Risk factors for atherosclerosis in SLE
Traditional atherosclerosis risk factors As defined in the Framingham heart studies, traditional risk factors for CVD are older age, male gender, smoking, high total cholesterol and LDL levels, high systolic blood pressure, diabetes mellitus, and left ventricular hypertrophy (Figure 2 ).
14 A comprehensive review of the epidemiology of traditional cardiovascular risk factors for atherosclerosis in SLE was recently published in this journal. 59 The influence of traditional risk factors for CVD in patients with SLE seems to be different from their contri bution in the nonautoimmune population, and the main focus of the clinician should be treating SLE whilst moni toring traditional CVD risk. 59 In the following sections we discuss nontraditional risk factors that might account for accelerated atherogenesis in patients with SLE ( Figure 2 ) and the potential for some of these risk factors to be used as biomarkers of CVD in SLE.
SLE-associated risk factors Disease activity, duration, and damage
Associations between SLE disease manifestations and atherosclerosis are not clear at present. The results of one crosssectional study suggested that high disease activ ity (assessed using the Systemic Lupus Activity Measure index) was associated with reduced atherosclerotic plaque burden, but longer disease duration positively correlated with plaque volume. 8 In another crosssectional cohort study, longer disease duration was also associated with higher coronary calcium. 60 Similarly, longer duration of SLE and higher levels of SLEassociated damage inde pendently predicted carotid plaque burden in a cross sectional 6 and a longitudinal study 7 in a different SLE cohort of a similar size.
Proinflammatory HDL
Although HDL levels partially determine atherosclerotic risk, HDL function is equally important. During the acute phase response, HDL can be converted from their usual antiinflammatory state into proinflammatory molecules that promote LDL oxidation (Figure 1 ). This acute phase response can also become chronic, which might represent a mechanism for HDL dysfunction in SLE. Indeed, our group has found that HDL function is proinflammatory (piHDL) in many women with SLE. 61 A followup study determined that >85% of patients with SLE and carotid plaques had measurable piHDL, compared with around 40% of those without detectable plaques. 30 piHDL levels have also been identified as an independent risk factor in RA 61, 62 and APS. 63 Therefore, assessment of piHDL could improve the prediction of atherosclerotic risk in patients with SLE; however, further longitudinal studies are required to clarify the association between piHDL and the development of fullblown CVD.
Oxidative stress
Oxidative stress-an excess of ROS not counterbalanced by an adequate antioxidant defense system-associates with accelerated atherosclerosis in the general popula tion. Increased oxidative stress has been identified in patients with SLE, and is often elevated independent of disease activity. 64 In one study, increased oxidative stress -assessed using urinary F2 isoprostane excretion-was associated with patientreported symptoms in SLE but not with inflammation or disease activity and damage scores. 64 More studies are required to assess contributions of ROS to atherosclerosis in SLE.
Homocysteine
High levels of plasma homocysteine have been linked to atherosclerosis in the general population. 65 Homocysteine is toxic to ECs, 66 is prothrombotic, 67, 68 decreases nitric oxide availability 69 and stimulates foam cell formation, 70 all of which suggest homocysteine is proatherogenic. High homocysteine levels result from both genetic effects and dietary inputs. Some studies have shown that elevated homocysteine levels in patients with SLE correlated with crosssectional 60,71-74 and longitudinal progression 7,48 of subclinical atherosclerosis, but others revealed no corre lation. 6, 9, 75 Renal insufficiency is a known cause of elevated homocysteine levels, 76 but the relationship between renal function and hyperhomocysteinemia in SLE has not been fully established.
Adipose-derived hormones
Adiposederived hormones-also known as adipokines or adipocytokines-produced by white adipose tissue regulate metabolism and energy homeostasis. One such protein is leptin, the main function of which in the hypo thalamus is suppression of appetite; however, leptin signal ing also contributes to atherosclerotic progression. 77 Elevated leptin levels have been observed in adult 78 and pediatric 79 patients with SLE. In addition, serum leptin levels were higher in patients with SLE and carotid plaques than in patients without plaques. 80 By contrast, high serum levels of another adipose derived hormone, adiponectin, are associated with low levels of adipose tissue and reduced risk of athero sclerosis and metabolic syndrome, and adiponectin levels are reduced in patients with CVD. Data linking adipo nectin concentrations and SLEassociated athero sclerosis are limited and contradictory: in one study, adiponectin levels were associated with carotid plaque, 81 but no correlation was found between adiponectin or leptin levels with coronary artery calcification in a sepa rate SLE cohort. 82 Thus, more research is required to establish the relationship between atherosclerosis and adiposederived hormone expression in patients with SLE.
Minimizing atherosclerotic risk in SLE
Minimizing Framingham risk factors A novel panel of tests for SLEspecific risk factors will probably be developed and validated in the future for the identification of patients at high risk of CVD. Such patients should be targeted for therapeutic interventions to prevent cardiovascular complications. Currently, however, our screening and treatment strategies are extrapolated from the best evidence available from research conducted in the general population. Expert panels in the USA and Europe recommend that patients with SLE should be annually screened for traditional modifiable risk factors for CVD, including smoking status, blood pressure, BMI, diabetes mellitus, and serum lipids (including total cholesterol, HDL, LDL and triglycerides). 83, 84 No randomized clinical trials of atherosclerosis prevention strategies have been performed specifically in SLE, however, so the current guidelines for modifying cardiovascular risk factors in patients with SLE are essentially the same as those aimed at reducing CVD in the general population.
Smoking
Smoking has been identified as a modifiable risk factor for atherosclerosis and CVD. As such, smoking cessation is recommended for patients with SLE. 84 
Diabetes mellitus
Diabetes mellitus is considered to be a coronary artery dis ease equivalent in the National Cholesterol Educa tion Panel guidelines; 85 treatment goals for patients with SLE and diabetes mellitus should aim to establish and main tain glycemic control, including minimizing gluco corticoid exposure.
Hypertension
The ideal blood pressure for patients with SLE is 130/80 mmHg, as recommended in the 7 th report of the Joint National Committee (JNC 7), 86 and is the same as for patients with other highrisk comorbid diseases-such as diabetes mellitus or chronic kidney disease. 86, 87 Difficulties associated with patient enrollment in trials of preventa tive strategies have precluded the establishment of an optimum atheroprotective therapeutic regimen in SLE. 88 Nevertheless, angiotensinconverting enzyme (ACE) inhibitors should be provided as the firstline therapy in patients with SLE and renal involvement. 89 The European League Against Rheumatism (EULAR) 90 also recommend ACE inhibitors as the induction therapy in hypertensive patients with inflammatory arthritis because of their potential favorable effects on inflammatory markers and EC function in RA. 90 Angiotensinreceptor blockers can also be considered in patients who cannot tolerate ACE inhibitor therapy. Thiazide diuretics are recommended as the primary therapy for hypertension in the general popu lation by JNC 7, 86 and would generally also be a safe choice in patients with SLE-although caution should be used, as thiazide diuretics can have dyslipidemic and diabeto genic effects. 87 βblockers have been shown to preci pitate Raynaud phenomenon, 91 and thus should be used with caution in individuals with SLE.
Treatment of hypercholesterolemia: statins
Statins are competitive inhibitors of 3hydroxy3 methylglutarylcoenzyme A (HMGCoA) reductase and are widely used to reduce cardiovascular morbidity. In addition to their lipidlowering properties, statins have a number of antiinflammatory effects, including inhibi tion of inflammatory cytokine production, ROS forma tion and Tcell activation, and upregulation of nitric oxide synthesis. 92 However, data on statin use for atherosclerosis prevention in SLE are inconsistent. For instance, in a short term (8 week) trial, atorvastatin improved ECdependent vasodilation, even after controlling for tradi tional cardio vascular risk factors. 93 Whereas, in a longer (2year) atorvastatin trial, statins did not prevent progression of coronary artery calcification or CIMT, and did not result in any marked improvements in disease activity, measures of systemic inflammation or EC activation. 94 Preventive trials in the general population have, however, benefited from much larger sample sizes and longer study durations than the SLE studies, and have shown statins to be safe and efficacious in preventing atherosclerotic progression. 95 Data from mouse models of atherosclerosis in SLE like disease have also been inconsistent; although statins resulted in improvement in atherosclerosis in one mouse model of SLE, 96 in Ldlr -/-mice reconstituted with bone marrow from lupusprone mice, statin treatment failed to attenuate atherogenesis despite reductions in cholesterol levels. 55 Therefore, the effectiveness of statin treatment in prevention of atherosclerotic progression in SLE is unclear and physicians prescribing statins for patients with SLE should adhere to guidelines from the National Cholesterol Education Panel. 83 
SLE therapy: implications for atherosclerosis
Antimalarial agents
Hydroxychloroquine is thought to be cardioprotec tive, although isolated reports of hydroxychloroquine REVIEWS cardio toxicity exist. 97 Hydroxychloroquine use has been associated with decreased aortic stiffness 98 and reduced plaque burden on carotid ultrasound images in patients with SLE. 6 Furthermore, antimalarials have been shown to minimize steroidinduced hypercholesterolemia. 99 In addition, hydroxychloroquine seems to be thrombo protective, showing association with a 68% reduction in the risk of all thrombovascular events in a case-control study in patients with SLE, 100 and thus might improve sur vival in SLE. Hydroxychloroquine might be cardioprotec tive in part because it interferes with the TLR7 and TLR9 signaling pathways.
101 TLR7 and TLR9 stimulation results in increased IFNα expression, which, as discussed above, is implicated in EC dysfunction and disrupts v ascular repair processes.
Glucocorticoids
Longer disease duration and high cumulative glucocorti coid dosage has been associated with atherosclerosis in patients with SLE. 8, 30, 71, 72, 102 In addition, prednisone doses >10 mg per day have been shown to independently predict high cholesterol levels in patients with SLE. 103 Conversely, lower prednisone use and cumulative dose were associated with plaque burden in a different SLE cohort, 6 suggest ing that the antiinflammatory effects of steroids can be atheroprotective when used in a specific (yet unknown) therapeutic window. Until such a dosage threshold is determined, we suggest following the EULAR recom mendation that the lowest possible dose of corticosteroids, determined on a patientbypatient basis, should be used. 90 Mycophenolate mofetil MMF-an immunosuppressive agent frequently used for SLE therapy-has several potential anti atherogenic effects. In animal models, MMF has been shown to inhibit NADPH oxidase, thereby reducing oxidative stress. 104 Furthermore, Ldlr -/-mice reconstituted with bone marrow from SLEprone strains had markedly reduced athero sclerotic burden and recruitment of CD4 + T cells to athero sclerotic plaques after MMF treatment. 55 Similarly, in patients with carotid artery stenosis, 2 weeks of MMF therapy resulted in decreased expression of inflam matory genes and numbers of activated T cells, and increased numbers of T REG cells in atherosclerotic plaques. 105 In addition, a retrospective study in patients with dia betes mellitus after renal transplant found a 20% decrease in cardio vascular mortality among patients treated with MMF compared with those prescribed immuno suppressive regimens that did not include MMF. 106 A small prospective observational study from our own group suggests that 12week treatment with MMF and hydroxy chloroquine, but not azathioprine, resulted in conversion of proinflammatory piHDL to a more normal, anti inflammatory form (McMahon, unpublished data). In a longitudinal cohort study, however, treatment of patients with SLE with MMF was not associated with a reduction in CIMT or coro nary artery calcification. 107 Larger, pro spective studies will need to be undertaken to clarify the potential of MMF to prevent progression of atherosclerosis in patients with SLE.
Azathioprine
In one retrospective case-control study, patients with SLE and documented coronary artery disease were more likely to have been treated with azathioprine than indivi duals without CVD. 108 Furthermore, in multivariate analy sis, azathioprine use was associated with cardiac events in the multiethnic LUMINA cohort, 29 and use of this agent correlated with increased CIMT in the APPLE trial. 109 Whether these associations are due to a direct effect of aza thio prine or the inability of azathioprine to over come the in flammation that leads to atherosclerosis is still not known.
B-cell-directed therapies
Although the role of B cells in progression of athero sclerosis is not currently well understood, some evidence sug gests that these cells might contribute to this process. In con trast to monocytes and T cells, however, activated B cells seem to be protective, as Bcell deficiency in atherosclerosisprone mice results in increased plaque burden. 110, 111 In addi tion, subsets of B cells produce atheroprotective molecules such as IL10 and antioxLDL antibodies. [110] [111] [112] As antiCD20 antibody therapy depletes B cells, an unintended consequence of treatment of SLE using this approach could be increased risk of CVD. Two studies, however, showed that Bcell depletion with antiCD20 antibodies considerably reduced plaque size in both the ApoE -/-and Ldlr -/-atherosclerosisprone mouse models, without affecting hyperlipidemia resulting from a highfat diet. 113, 114 In the ApoE -/-model, antiCD20 antibody treat ment reduced Tcell activation, and preserved antioxLDL IgM antibodies whilst reducing antioxLDL IgG anti bodies. 114 Improved lipid profiles have been observed in patients with SLE after antiCD20 therapy; 115 however, as observed in studies reporting the presence of dysfunc tional piHDL-which is not measured by standard clinical lipid analysis-and the ineffectiveness of statin therapy in SLE, improved lipid levels do not always predict a reduc tion in athero sclerosis. As antiCD20 and antiBAFF (Bcellactivating factor, also known as TNF ligand super family member 13B or Blymphocyte stimulator) therapies have only recently been introduced into clinical practice, how Bcelldirected therapy will influence atherosclerosis in patients with SLE remains to be determined.
Novel therapeutics to prevent atherosclerosis
The potential of peptides mimicking HDLrelated pro teins such as apoAI and apolipoprotein J (apoJ) to prevent atherosclerosis is currently the subject of intense study. ApoAI and apoJ peptides convert piHDL back to normal HDL by binding and promoting removal of oxidized lipids from the circulation. 116, 117 Thus, normal activity of anti inflammatory HDL is restored and LDL particles are pro tected from oxidation. Both the apoAI peptide 4F and an apoJ peptide, [113122]apoJ, improve vasodilation impairment and cause plaque regression in animal models of athero sclerosis. 116, 117 4F treatment, alone or with prava statin, markedly reduced SLElike disease and, despite increased lesion size, resulted in potentially benefi cial remodeling of atherosclerotic plaques in a mouse model of SLE with accelerated atherosclerosis. 118 In the future, apolipoprotein mimetic peptides might be effective, non toxic therapeutic options for reduction of disease activity and CVD risk in patients with SLE. Evidence for a role of IFNα at multiple points in the pathogenesis of atherosclerosis has emerged; potential IFNαdriven aberrations in EC apoptosis, EPCs and CACs survival or differentiation, and vasculogenesis in SLE has been discussed above. 21, 45, 119 In addition, priming of macrophages with IFNα increases their uptake of oxLDL. 120 Several IFNα inhibitors are currently being evaluated in clinical trials in SLE, and future studies will be required to determine whether these medications are protective against atherosclerosis in patients with SLE.
Guidelines for monitoring CVD risk in SLE EULAR recommends that patients with SLE 121 or RA 90 should be monitored for increased cardiac risk. In RA, EULAR guidelines list 10 unique parameters for manag ing CVD risk, including minimizing cortico steroid expo sure, monitoring serum lipid levels, and traditional Framing ham or Systematic Coronary Risk Evalu ation risk assessment. 90 In SLE, the EULAR guidelines are not CVDspecific, and only one of the 10 recommendations deals with CVD risk. 121 Statin use is also recommended for patients with RA, although, as discussed above, use of these agents might not be effective in slowing progression of atherosclerosis in human and mouse SLE. CVDspecific guidelines for SLE, akin to the EULAR recommendations for RA, would be a valuable tool for rheumatologists.
Conclusions
Atherosclerosis and CVD are major causes of morbidity and mortality in multiple rheumatic diseases. We do not yet fully understand what causes accelerated athero sclerosis in autoimmune diseases. Nevertheless, evidence strongly suggests that the complex interplay between dysfunctional immune regulation, inflammation, traditional risk factors, defective EC function and vascular repair, and therapeu tics used to treat the underlying auto immune disease influence this process. Data also suggest that SLEspecific factors could contribute to increased atherosclerotic risk. A comprehensive biomarker panel incorporating these SLEspecific and traditional CVD risk factors (homo cysteine, lipid levels, and so on) could be an essential tool for identifying patients at risk of acceler ated atherosclerosis soon after diagnosis of SLE. Clinical biomarkers for some of these risk factors are still in development (analysis of piHDL and EPC or CAC levels, for example). The clini cal complexity of accelerated athero sclerosis will probably require an integrated approach to identifying and treating atrisk patients. Intensive study into this aspect of SLE will ultimately lead to improved cardiovascular outcomes.
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